DOCSLIB.ORG

FDA Briefing Document Pretomanid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FDA Briefing Document Pretomanid FDA Briefing Document Pretomanid Tablet, 200 mg Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) June 06, 2019 The committee will discuss new drug application (NDA) 212862 1 The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the Advisory Committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. The FDA have brought Pretomanid tablets to this Advisory Committee to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the Advisory Committee. The FDA will not issue a final determination on the issues at hand until input from the Advisory Committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the Advisory Committee meeting. 2 Table of Contents 1 Introduction ........................................................................................................................................... 4 2 Background ............................................................................................................................................ 4 3 Product Information ............................................................................................................................... 4 4 Regulatory History ................................................................................................................................. 4 5 Clinical Pharmacology ........................................................................................................................... 5 6 Microbiology ......................................................................................................................................... 7 7 Pharmacology/Toxicology ..................................................................................................................... 9 8 Overview of Clinical Development Program ........................................................................................11 8.1 Study Nix-TB ...............................................................................................................................13 8.1.1 Study Design............................................................................................................................13 8.1.2 Statistical Methodologies.........................................................................................................17 8.1.3 Patient Disposition ...................................................................................................................18 8.1.4 Efficacy Results .......................................................................................................................23 8.2 Summary and Conclusions of Efficacy ........................................................................................34 9 Evaluation of Safety .............................................................................................................................35 9.1 Safety Summary ...........................................................................................................................35 9.2 Methods .......................................................................................................................................35 9.3 Adverse Event Analysis ...............................................................................................................35 9.4 Adverse Reactions of Special Interest and Submission Specific Safety Issues ............................40 9.4.1 Hepatobiliary ...........................................................................................................................40 9.4.2 Ophthalmic ..............................................................................................................................42 9.4.3 Fertility ....................................................................................................................................43 9.4.4 Cardiac .....................................................................................................................................44 9.4.5 Hematologic.............................................................................................................................44 9.4.6 Neurologic ...............................................................................................................................45 9.4.7 Pancreatic ................................................................................................................................46 9.4.8 Lactic Acidosis ........................................................................................................................47 9.5 Phase 1 Pooled Studies ................................................................................................................47 9.6 Phase 2 Pooled Studies ................................................................................................................50 9.7 Summary of Safety ......................................................................................................................51 10 Draft Points for Advisory Committee Discussion ................................................................................52 3 1 Introduction This briefing document prepared by the FDA for panel members of the Antimicrobial Drugs Advisory Committee describes the safety and efficacy data for pretomanid. The FDA would like the committee to discuss whether the data are adequate to support the safety and efficacy of pretomanid as part of a regimen (B-L-Pa: bedaquiline, linezolid, pretomanid) for treatment-intolerant/nonresponsive multi-drug resistant tuberculosis (TI/NR MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). 2 Background Pretomanid (also known as PA-824) is not currently marketed in the US or anywhere in the world. In the NDA, pretomanid was evaluated as part of an oral regimen in combination with bedaquiline and linezolid for the treatment of TI/NR MDR-TB and XDR-TB. 3 Product Information Pretomanid is a nitroimidazooxazine antimycobacterial drug. Each immediate-release tablet contains 200 mg of pretomanid. 4 Regulatory History Clinical trials of pretomanid (> 14 days of treatment) in various antimycobacterial drug regimens are summarized in Table 8-1. Pretomanid was granted orphan drug designation and Fast Track designation for the treatment of tuberculosis, and Qualified Infectious Disease Product (QIDP) designation for the treatment of DS-TB, MDR-TB and XDR-TB. The NDA was granted a priority review. The applicant and the Agency agreed that an interim clinical study report (CSR) providing safety and efficacy data on the first 45 subjects assessed for the primary efficacy endpoint in the ongoing single-arm Phase 3 trial (Nix-TB) in patients with XDR- TB and TI/ NR MDR-TB would be acceptable to support an NDA submission. In addition, the Agency agreed that an addendum to the CSR with updated efficacy and safety data on all 109 enrolled subjects could be included in the initial NDA submission. To support the efficacy outcomes in Nix-TB, the applicant agreed to provide a literature summary and case-matched analysis of historical control data for XDR-TB patients. Other agreements between the applicant and the Agency included: • Ophthalmological evaluations for cataract formation would be incorporated in clinical trials of pretomanid dosed for more than 14 days, based on a signal for cataract formation in nonclinical studies. 4 • The signal for male infertility observed in animal toxicology studies of pretomanid would be further investigated clinically, including evaluations of male hormone levels in clinical trials and a semen analysis study in human subjects. • Additional hepatic impairment and renal impairment pharmacokinetic (PK) studies would be conducted concurrent with the NDA. As agreed with the Agency at the pre-NDA meeting, results of the semen analysis study and the hepatic impairment and renal impairment PK studies will not be available until after NDA review. 5 Clinical Pharmacology Absorption Pretomanid exposures were approximately dose-proportional over a dose range from 50 to 200 mg. At doses greater than 200 mg, exposure increased in a less than dose- proportional manner. Steady-state pretomanid plasma concentrations were achieved at approximately 4 to 6 days following multiple dose administration of 200 mg and the accumulation ratio was approximately 2. Administration of a 200 mg dose of pretomanid with a high-fat, high-calorie meal increased mean Cmax by 76% and mean AUC∞ by 88% as compared with the fasted state. PK parameters following single and multiple 200 mg doses of pretomanid in healthy adult subjects are summarized in Table 5-1. Table 5-1. Pretomanid Pharmacokinetic Parameters in Healthy Adult Subjects Under Fasted and Fed Conditions Single Dose Single Dose Steady State PK Parameter 200 mg; Fasted 200 mg; Fed 200 mg QD; Fasted Cmax (µg/mL) 1.1 (0.2) 2.0 (0.3) 1.7 (0.3) § AUCt(µg•hr/mL) 28.1 (8.0) 51.6 (10.1) 30.2 (3.7) # AUCinf (µg•hr/mL)
Load more

Recommended publications
  • Clofazimine As a Treatment for Multidrug-Resistant Tuberculosis: a Review
    Scientia Pharmaceutica Review Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review Rhea Veda Nugraha 1 , Vycke Yunivita 2 , Prayudi Santoso 3, Rob E. Aarnoutse 4 and Rovina Ruslami 2,* 1 Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia; [email protected] 2 Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia; [email protected] 3 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran—Hasan Sadikin Hospital, Bandung 40161, Indonesia; [email protected] 4 Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, 6255HB Nijmegen, The Netherlands; [email protected] * Correspondence: [email protected] Abstract: Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease caused by Mycobac- terium tuberculosis which is resistant to at least isoniazid and rifampicin. This disease is a worldwide threat and complicates the control of tuberculosis (TB). Long treatment duration, a combination of several drugs, and the adverse effects of these drugs are the factors that play a role in the poor outcomes of MDR-TB patients. There have been many studies with repurposed drugs to improve MDR-TB outcomes, including clofazimine. Clofazimine recently moved from group 5 to group B of drugs that are used to treat MDR-TB. This drug belongs to the riminophenazine class, which has lipophilic characteristics and was previously discovered to treat TB and approved for leprosy. This review discusses the role of clofazimine as a treatment component in patients with MDR-TB, and Citation: Nugraha, R.V.; Yunivita, V.; the drug’s properties.
    [Show full text]
  • Inhaled Anti-Tubercular Therapy: Dry Powder Formulations, Device And
    UNI SYDNEY LOGO INHALED ANTI-TUBERCULAR THERAPY: DRY POWDER FORMULATIONS, DEVICE AND TOXICITY CHALLENGES Thaigarajan Parumasivam A thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy Faculty of Pharmacy The University of Sydney 2017 STATEMENT OF AUTHENTICITY This thesis is submitted to the University of Sydney in fulfilment of the requirements for the Degree of Doctor of Philosophy. The work described was carried out in the Faculty of Pharmacy and Centenary Institute under the supervision of Professor Hak-Kim Chan and Professor Warwick Britton The work presented in this thesis, is to the best of my knowledge and belief, original except as acknowledged in the text. The contributions of all co-authors in publications included in the body of the thesis have been declared, signed by each co-author and attached as an appendix. I hereby declare that I have not previously or concurrently submitted this material, either in full or in part, for a degree at this or any other institution. Thaigarajan Parumasivam Oct 2016 ii CONTENTS Acknowledgement ................................................................................................................. viii Glossary .................................................................................................................................... x Thesis abstract .......................................................................................................................... 1 Chapter 1 .......................................................................................................................
    [Show full text]
  • Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
    AMERICAN THORACIC SOCIETY DOCUMENTS Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley, Jan L. Brozek, Adithya Cattamanchi, J. Peter Cegielski, Lisa Chen, Charles L. Daley, Tracy L. Dalton, Raquel Duarte, Federica Fregonese, C. Robert Horsburgh, Jr., Faiz Ahmad Khan, Fayez Kheir, Zhiyi Lan, Alfred Lardizabal, Michael Lauzardo, Joan M. Mangan, Suzanne M. Marks, Lindsay McKenna, Dick Menzies, Carole D. Mitnick, Diana M. Nilsen, Farah Parvez, Charles A. Peloquin, Ann Raftery, H. Simon Schaaf, Neha S. Shah, Jeffrey R. Starke, John W. Wilson, Jonathan M. Wortham, Terence Chorba, and Barbara Seaworth; on behalf of the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY, THE EUROPEAN RESPIRATORY SOCIETY, AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA SEPTEMBER 2019, AND WAS CLEARED BY THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION SEPTEMBER 2019 Background: The American Thoracic Society, U.S. Centers for was judged to be very low, because the data came Disease Control and Prevention, European Respiratory Society, and from observational studies with significant loss to follow-up Infectious Diseases Society of America jointly sponsored this new and imbalance in background regimens between comparator practice guideline on the treatment of drug-resistant tuberculosis groups. Good practices in the management of MDR-TB are (DR-TB). The document includes recommendations on the described. On the basis of the evidence review, a clinical strategy treatment of multidrug-resistant TB (MDR-TB) as well as tool for building a treatment regimen for MDR-TB is also isoniazid-resistant but rifampin-susceptible TB.
    [Show full text]
  • Pretomanid Reference Number: CP.PMN.222 Effective Date: 03.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log
    Clinical Policy: Pretomanid Reference Number: CP.PMN.222 Effective Date: 03.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Pretomanid is a nitroimidazooxazine antimycobacterial drug. FDA Approved Indication(s) Pretomanid is indicated as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitation(s) of use: • Pretomanid tablets are not indicated for patients with: o Drug-sensitive (DS) tuberculosis o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy • Safety and effectiveness of pretomanid tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that pretomanid is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Multi-Drug Resistant Tuberculosis (must meet all): 1. Diagnosis of pulmonary MDR-TB or XDR-TB; 2. Prescribed by or in consultation with an expert in the treatment of tuberculosis; 3.
    [Show full text]
  • Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations
    applied sciences Review Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations Rob C. van Wijk 1 , Rami Ayoun Alsoud 1, Hans Lennernäs 2 and Ulrika S. H. Simonsson 1,* 1 Department of Pharmaceutical Biosciences, Uppsala University, Uppsala 75123, Sweden; [email protected] (R.C.v.W.); [email protected] (R.A.A.) 2 Department of Pharmacy, Uppsala University, Uppsala 75123, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +46-184-714-000 Received: 29 February 2020; Accepted: 25 March 2020; Published: 31 March 2020 Featured Application: Model-informed drug discovery and development (MID3) is proposed to be applied throughout the preclinical to clinical phases to provide an informative prediction of drug exposure and efficacy in humans in order to select novel anti-tuberculosis drug combinations for the treatment of tuberculosis. Abstract: The increasing emergence of drug-resistant tuberculosis requires new effective and safe drug regimens. However, drug discovery and development are challenging, lengthy and costly. The framework of model-informed drug discovery and development (MID3) is proposed to be applied throughout the preclinical to clinical phases to provide an informative prediction of drug exposure and efficacy in humans in order to select novel anti-tuberculosis drug combinations. The MID3 includes pharmacokinetic-pharmacodynamic and quantitative systems pharmacology models, machine learning and artificial intelligence, which integrates all the available knowledge related to disease and the compounds. A translational in vitro-in vivo link throughout modeling and simulation is crucial to optimize the selection of regimens with the highest probability of receiving approval from regulatory authorities.
    [Show full text]
  • Appraisal of NICE's Cost-Effectiveness Thresholds for Assessing Orphan
    Master's Degree Dissertation Appraisal of NICE’s cost-effectiveness thresholds for assessing orphan drugs Author: Ruodan Nan Master's Degree in Health Economics and Pharmacoeconomics UPF Barcelona School of Management Academic Year 2018 – 2021 Mentor: Laura Vallejo 1 Project performed within the framework of the Health Economics and Pharmacoeconomics program taught by Barcelona School of Management, a centre associated with Pompeu Fabra University 2 Abstract A rare disease is one that affects less than 1 in 2,000 in general population, and they are often chronic and life-threatening [1]. Due to the high cost to develop and small market for orphan drugs, historically manufacturers are reluctantly to explore the rare disease therapeutic areas. There is highly unmet need from patients with rare diseases. As the pharmaceutical expenditure rises, governments around the world are increasingly under pressure to contain the costs on drug reimbursement. Meanwhile patients with rare diseases need to be ensured for access to orphan drugs, and the industry needs to be incentivized to innovate. Health technology assessment and reimbursement bodies set out measures and policies for orphan drugs to be given market access. In this literature review, the landscape of health technology appraisals for orphan drugs in England UK is studied. The process for an orphan drug to gain marketing authorisation in the European Union (EU), the methods and criteria that used by National Institute for Health and Care Excellence (NICE) are reviewed. All orphan drugs with marketing authorisations from European Medicine Agency (EMA) are searched from the agency’s online database, whereas each of the authorised orphan drug is searched in NICE’s database for any technology appraisals and recommendations made for the orphan drug.
    [Show full text]
  • Orphan Maintenance Assessment Report
    31 July 2020 EMADOC-1700519818-446338 Correction1 EMA/OD/0000021750 Committee for Orphan Medicinal Products Orphan Maintenance Assessment Report Pretomanid FGK (pretomanid) Treatment of tuberculosis EU/3/07/513 Sponsor: FGK Representative Service GmbH Note COMP with all information of a commercially confidential nature deleted. 1 Significant benefit subheading: typographical corrections on pages 6 and 7 and addition of contextualisation sentence on page 6, adopted on 8 October 2020 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Product and administrative information .................................................. 3 2. Grounds for the COMP opinion ................................................................ 4 3. Review of criteria for orphan designation at the time of marketing authorisation .............................................................................................. 4 Article 3(1)(a) of Regulation (EC) No 141/2000 .............................................................. 4 Article 3(1)(b) of Regulation (EC) No 141/2000 .............................................................. 5 4. COMP list of issues .................................................................................
    [Show full text]
  • Full Text Article
    SJIF Impact Factor: 5.464 WORLD JOURNAL OF ADVANCE ISSN: 2457-0400 Swarna et al. World Journal of Advance HealthcareVolume: Research 5. HEALTHCARE RESEARCH Issue: 3. Page N. 425-437 Year: 2021 Review Article ww.wjahr.com PREDISPOSING FACTORS AND DEVELOPMENT OF RESISTANCE TO MYCOBACTERIUM TUBERCULI Swarna Priya B.*, Tharun Kanduri1 and P. Chetan Sai2 *Doctor of Pharmacy V year, Department of Pharmacy Practice, Jaya College of Pharmacy, Thiruninravur, Chennai, Tamil Nadu, India. 1,2Doctor of Pharmacy IV year, Department of Pharmacy Practice, Sri Venkateswara College of Pharmacy, Madhapur, Telangana, India. Received date: 03 April 2021 Revised date: 24 April 2021 Accepted date: 14 May 2021 *Corresponding author: Swarna Priya B. Doctor of Pharmacy V year, Department of Pharmacy Practice, Jaya College of Pharmacy, Thiruninravur, Chennai, Tamil Nadu, India. ABSTRACT Tuberculosis (TB) is one of the highly prevalent disease worldwide with the increase in severity and mortality as well. The disease is now a huge public health concern with the effect in association with resistance, resulting in poor health outcomes and huge community spread. The resistance formed makes it more vulnerable towards treatment regimens. This type of resistance can result in multiple drug intake and can poses a greater threat for major health complications as well in future. The current article is built on the different sequences in development of multi drug resistance in tuberculosis and also defines the strategies used to reduce the major public health concern of health outcomes in India. KEYWORDS: Tuberculosis, Highly Prevalent, Mortality, Community spread, Multi Drug resistance, Health Outcomes. INTRODUCTION ≥15) accounted for 56%, women (aged ≥15years) 32% and children (aged ≤15 years) 12%.
    [Show full text]
  • Mechanisms of Drug Resistance in Mycobacterium Tuberculosis: Update 2015
    INT J TUBERC LUNG DIS 19(11):1276–1289 STATE OF THE ART Q 2015 The Union http://dx.doi.org/10.5588/ijtld.15.0389 Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015 Y. Zhang,* W-W. Yew† *Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA; †Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong SAR, China SUMMARY Drug-resistant tuberculosis (DR-TB), including multi- resistance. However, further research is needed to and extensively drug-resistant TB, is posing a significant address the significance of newly discovered gene challenge to effective treatment and TB control world- mutations in causing drug resistance. Improved knowl- wide. New progress has been made in our understanding edge of drug resistance mechanisms will help understand of the mechanisms of resistance to anti-tuberculosis the mechanisms of action of the drugs, devise better drugs. This review provides an update on the major molecular diagnostic tests for more effective DR-TB advances in drug resistance mechanisms since the management (and for personalised treatment), and previous publication in 2009, as well as added informa- facilitate the development of new drugs to improve the tion on mechanisms of resistance to new drugs and treatment of this disease. repurposed agents. The recent application of whole KEY WORDS: antibiotics; drug resistance; mechanisms; genome sequencing technologies has provided new molecular diagnostics; new drugs insight into the mechanisms and complexity of drug The use of multiple-drug therapy, although defi- drug-resistant TB (DR-TB) epidemic thus remains nitely beneficial, is not an absolute guarantee an alarming problem, and is further aggravated by against the emergence of drug-resistant in- human immunodeficiency virus (HIV) coinfection.3 fections.
    [Show full text]
  • U.S. Food and Drug Administration (FDA) Approves Pretomanid
    U.S. Food and Drug Administration (FDA) Approves Pretomanid On August 14, 2019 the FDA granted approval for Pretomanid Tablets to the nonprofit Global Alliance for TB Drug Development (TB Alliance). Pretomanid is approved for use as part of a three-drug regimen with bedaquiline and linezolid to treat adults with pulmonary extensively drug-resistant (XDR), or to treat intolerant or nonresponsive multidrug-resistant (MDR) TB1. The three-drug, six-month, all oral regimen is also referred to as BPal (for bedaquiline, pretomanid and linezolid). As described in the FDA press release announcing the approval, “the safety and effectiveness of Pretomanid, taken orally in combination with bedaquiline and linezolid, was primarily demonstrated in a study of 109 patients with extensively drug-resistant, treatment intolerant or non-responsive multidrug-resistant pulmonary TB (of the lungs). Of the 107 patients who were evaluated six months after the end of therapy, 95 (89 percent) were successes, which significantly exceeded the historical success rates for treatment of extensively drug resistant TB.” In April 2019, TB Alliance granted a non-exclusive, worldwide license to pharmaceutical company Mylan for the manufacture and commercialization of Pretomanid. The drug is expected to be available in the U.S. by the end of calendar year 20192. Pretomanid is the second drug to be approved under the Limited Population for Antibacterial and Antifungal Drugs (LPAD) Pathway. This was added to the Federal Food, Drug and Cosmetic Act by Section 3042 of the 21st Century Cures Act enacted by the U.S. Congress in 2016. The intent of the LPAD Pathway is to facilitate the development of antibacterial (and antifungal) drug products that treat serious or life-threatening infections.
    [Show full text]
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
    Effective 6/11/2020. Contact [email protected] for previous versions. Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline Note: Active Table of Contents – Click to follow link INTRODUCTION........................................................................................................................... 3 SCOPE....................................................................................................................................... 3 DEFINITIONS .............................................................................................................................. 3 RECOMMENDATIONS ................................................................................................................... 4 METHODOLOGY .........................................................................................................................28 COLLATERAL TOOLS & RESOURCES..................................................................................................31 APPENDIX A: PERIOPERATIVE MEDICATION MANAGEMENT .................................................................32 APPENDIX B: TREATMENT ALGORITHM FOR THE TIMING OF ELECTIVE NONCARDIAC SURGERY IN PATIENTS WITH CORONARY STENTS .....................................................................................................................58 APPENDIX C: METHYLENE BLUE AND SEROTONIN SYNDROME ...............................................................59 APPENDIX D: AMINOLEVULINIC ACID AND PHOTOTOXICITY
    [Show full text]
  • Evolution of Drug Resistance in Mycobacterium Tuberculosis: a Review on the Molecular Determinants of Resistance and Implications for Personalized Care
    CORE Metadata, citation and similar papers at core.ac.uk Provided by ResearchSpace@UKZN J Antimicrob Chemother 2018; 73: 1138–1151 doi:10.1093/jac/dkx506 Advance Access publication 19 January 2018 Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care Navisha Dookie1*, Santhuri Rambaran1, Nesri Padayatchi1,2, Sharana Mahomed1 and Kogieleum Naidoo1,2 1Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; 2South African Medical Research Council (SAMRC) - CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa *Corresponding author. CAPRISA, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Private Bag X7, Congella, 4013 South Africa. Tel: !27 31 260 4703; Fax: !27 31 260 4549; E-mail: [email protected] Drug-resistant TB (DR-TB) remains a significant challenge in TB treatment and control programmes worldwide. Advances in sequencing technology have significantly increased our understanding of the mechanisms of resistance to anti-TB drugs. This review provides an update on advances in our understanding of drug resistance mechanisms to new, existing drugs and repurposed agents. Recent advances in WGS technology hold promise as a tool for rapid diagnosis and clinical management of TB. Although the standard approach to WGS of Mycobacterium tuberculosis is slow due to the requirement for organism culture, recent attempts to sequence directly from clinical specimens have improved the potential to diagnose and detect resistance within days. The introduction of new databases may be helpful, such as the Relational Sequencing TB Data Platform, which contains a collection of whole-genome sequences highlighting key drug resistance mutations and clinical outcomes.
    [Show full text]